J&J To Power Ahead With 10 Launches In Four Years

Set To Outpace Sector Again

Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further.

Johnson & Johnson has sustained remarkable growth in recent years, and a raft of new products are set to help them maintain this form.

Johnson & Johnson’s pharma division looks set to outperform its peers thanks to a portfolio of fast-growing products and up to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

09 May 2025

• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

09 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.